key: cord-0866604-oeojcqmf
authors: Gazzaruso, Carmine; Carlo Stella, Nicoletta; Mariani, Giuseppe; Nai, Carlo; Coppola, Adriana; Naldani, Daniela; Gallotti, Pietro
title: High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia
date: 2020-05-27
journal: Clin Rheumatol
DOI: 10.1007/s10067-020-05180-7
sha: 909883c25d334b68bf00d348b2605c8506035a00
doc_id: 866604
cord_uid: oeojcqmf

nan

pneumonia. Pneumonia was documented by computed tomography and infection was established by RT-PCR. Blood samples were taken on admission. Statistical analysis was performed with t test after log-transformation for non-normally distributed variables and with exact Fisher test for frequency comparisons. Table 1 shows features of the patients, prevalence of autoimmune markers, and features of the patients stratified by presence/absence of ANA and lupus anticoagulant. Several autoimmune markers were present. The prevalence of antinuclear antibodies (ANA) (35.6%) and lupus anticoagulant (11.1%) was very high. Moreover, borderline values of lupus anticoagulant were present in a high percentage of subjects (35.5%). No difference was found between subjects with positive and those with borderline lupus anticoagulant, so we grouped the two together in our analysis.

The high prevalence of ANA, together with other autoimmune markers, suggests an involvement of autoimmune mechanisms in SARS2-CoV2 disease. In addition, lupus anticoagulant may be associated with the increased thrombotic risk described in a high proportion of patients and characterized by cardiac involvement, respiratory complications, and death [2] . The prevalence of lupus anticoagulant in our patients is similar to that recently reported [5] : indeed, if we group together subjects with positive and those with borderline values of lupus anticoagulant, the prevalence becomes impressively high (46.6%). On the other hand, we cannot exclude that borderline values of lupus anticoagulant early detected on admission will become positive in a subsequent short time. No significant differences in C-reactive protein, D-dimer, prothrombin time, and activated partialthromboplastin time were observed between subjects with and without ANA or lupus anticoagulant. The lack of difference in D-dimer between patients with and without lupus anticoagulant may be surprising, but this may be due to the fact that inflammation can affect D-dimer levels and that our study population is relatively small. The significant association of both cardiac troponin and oxygen saturation with lupus anticoagulant may be of clinical interest, as it may predict a worse course of pneumonia, characterized by thrombotic complications and death. However, specific studies have to confirm this hypothesis. In conclusion, our data suggest a possible role of autoimmune mechanisms in SARS-CoV2 pneumonia requiring hospitalization and this may imply specific treatments. Other studies should clarify whether lupus anticoagulant can be used to stratify patients at high risk for cardiovascular involvement and thrombosis and whether it can predict poorer outcomes of viral pneumonia, including death. Author contributions CG and PG contributed to concept, design and supervision of the study, interpretation of data, and writing the manuscript. CG and AC performed statistical analysis. NCS, GM, CN, AC, and DN contributed to the acquisition and interpretation of data and critical revision of the manuscript.

Disclosures None.

Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Lupus anticoagulant is frequent in patients with Covid-19

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations